IMMUTEP LTD. news, videos and press releases
For more news please use our advanced search feature.
IMMUTEP LTD. - More news...
IMMUTEP LTD. - More news...
- Immutep Quarterly Activities Report Q2 FY25
- Patient Enrolment Completed for EFTISARC-NEO Phase II Trial
- Patient Enrolment Completed for INSIGHT-003
- Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761
- Immutep and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class II
- Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024
- Immutep Announces Initiation of TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer
- Immutep’s Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer
- Positive Data from Phase II Trial in Soft Tissue Sarcoma Presented at CTOS 2024 Annual Meeting
- Immutep Quarterly Activities Report Q1 FY25
- Immutep to Present New Phase IIb Data in PD-L1 Negative (CPS <1) Head and Neck Cancer at ESMO Immuno-Oncology 2024
- Immutep Announces First-in-Human Phase I Study of IMP761 Progresses to Dose Escalation Portion of Trial
- Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit
- Immutep Completes Patient Enrolment in Randomised Phase II of AIPAC-003 Trial in Metastatic Breast Cancer
- Immutep Receives A$3.6 million R&D Tax Incentive from French Government
- New Data to be Presented from EFTISARC-NEO Phase II Evaluating Novel Triple Combination including Immutep’s Efti in Soft Tissue Sarcoma
- Immutep’s Efti in Combination with MSD’s KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer
- Immutep Announces Late-Breaking Abstract in Head & Neck Cancer Selected for Oral Presentation at ESMO Congress 2024
- Immutep Announces First Participant Dosed in Phase I Study of IMP761, a First in Class Agonist LAG-3 Antibody
- Immutep to Participate in Upcoming Investor Conferences
- Immutep Quarterly Activities Report Q4 FY24
- Immutep Announces Successful Meeting with FDA on Phase III Design in Non-Small Cell Lung Cancer
- Immutep Receives Regulatory Clearance for Phase I Study of First-in-Class LAG-3 Agonist Antibody Designed to Treat Autoimmune Diseases
- Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression
- Immutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss Clinical Results
- Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer
- Immutep successfully completes institutional placement and institutional component of entitlement offer
- Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial
- Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024
- Positive Initial Clinical Data Reported from Immutep’s Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma
